孕激素受体基因多态性+331G/A hPR是否会影响接受激素治疗的绝经后女性发生静脉血栓栓塞的风险？埃丝特研究。
Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.
作者信息
Bouaziz Elodie, Canonico Marianne, Verstuyft Céline, Carcaillon Laure, Martin Frédéric, Scarabin Pierre-Yves, Guiochon-Mantel Anne
机构信息
Laboratoire de Génétique moléculaire, Pharmacogénétique et Hormonologie, Hôpital Bicêtre, AP-HP, Univ Paris-Sud, 78, rue du Général Leclerc, F-94275 Le Kremlin Bicêtre Cedex, France.
出版信息
Maturitas. 2009 Oct 20;64(2):136-8. doi: 10.1016/j.maturitas.2009.08.013. Epub 2009 Sep 25.
Hormone therapy (HT) increases venous thromboembolism (VTE) risk among postmenopausal women. Data on the influence of steroids receptors polymorphisms on this association remain scarce. Since progesterone receptor (hPR) is expressed in human veins and specific progestogens increase VTE risk, we investigated the impact of the functional +331G/A hPR polymorphism on the association of VTE with HT. Using the data of the ESTHER study, we showed that ORs for VTE in current users of progesterone or progestins were not significantly different by hPR+331G/A genotype status. hPR polymorphism appears not to have a significant effect on VTE risk related to HT.
激素疗法（HT）会增加绝经后女性发生静脉血栓栓塞（VTE）的风险。关于类固醇受体多态性对这种关联影响的数据仍然很少。由于孕激素受体（hPR）在人体静脉中表达，且特定的孕激素会增加VTE风险，我们研究了功能性+331G/A hPR多态性对VTE与HT关联的影响。利用ESTHER研究的数据，我们发现，孕激素或孕激素类药物当前使用者中VTE的比值比（OR）在hPR +331G/A基因型状态方面并无显著差异。hPR多态性似乎对与HT相关的VTE风险没有显著影响。
Zotero 插件